Lyme vaccine designed to target the 2 key outer surface proteins (Osps) involved in disease transmission for a full level of protection
Proven to induce borreliacidal antibodies that bind to OspA and OspC, forming a complex that attacks the cell membrane and kills Borrelia burgdorferi1,5
Proven to help prevent clinical disease such as arthritis – as well as at the subclinical level 5
Highly effective: no serologic evidence of exposure to Borrelia burgdorferi5
INDICATIONS:
For the vaccination of healthy dogs as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi.
Recommended for use in healthy dogs 8 weeks of age or older.
Efficacy
2. MORTALITY: THE ONLY LEPTOSPIROSIS VACCINE SHOWN TO BE EFFECTIVE AGAINST DISEASE AND MORTALITY
PROTECTION FOR DOGS FACING THE MOST SEVERE CHALLENGES21
No dogs vaccinated with Nobivac® Canine 1-DAPPv+L4 died or required euthanasia
54% mortality and euthanasia in control groups, reflecting the severity of challenge
Clinical efficacy results showed that Nobivac® Canine 1-DAPPv+L4 also prevented1
Leptospiremia
More than 85% of vaccinates had no leptospiremia; leptospires were cleared quickly from the blood in those that did
By contrast, all control dogs had leptospiremia, and it lasted significantly longer, by days
Liver dysfunction
Serum levels of bilirubin and AST* remained at normal levels in significantly more vaccinates
Thrombocytopenia
Platelet counts remained in the normal range
* AST = aspartate aminotransferase
ANTIBODY ACTIVITY
THE BORRELIACIDAL DIFFERENCE
Only Nobivac® Lyme induces borreliacidal activity against both OspA and OspC1,5,80
Not all antibody responses are the same.
“Multi-Osp protection” that induces antibodies against Osps other than OspA and OspC has not been shown to be relevant5,29,30
Other Lyme vaccines may induce antibodies against OspC, but they are not borreliacidal—meaning they don’t kill Borrelia burgdorferi
As a result, vaccines that only induce borreliacidal antibodies against OspA provide incomplete protection once OspC becomes the dominant protein expressed in the tick
Only Nobivac Lyme induces OspC borreliacidal antibodies that kill spirochetes in the tick midgut, those migrating from the midgut to the tick’s salivary glands, and those introduced into the dog80
COMPETITIVE COMPARISON
ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.
COMPETITIVE COMPARISON
ONLY NOBIVAC® LYME OFFERS POWERFUL COMPARATIVE BENEFITS AND PROVEN SAFETY.
PREVENTS JOINT ABNORMALITIES
NOBIVAC® LYME IS SHOWN TO BE EFFECTIVE AGAINST SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE5
Following vaccination with Nobivac Lyme:
No Borrelia burgdorferi were found in the joint
No joint inflammation, stiffness, or lameness were observed5
40% of control dogs developed chronic joint inflammation5
27% of control dogs developed joint stiffness or lameness5
Dogs exhibited no signs of Lyme disease–associated joint abnormalities5
PREVENTS JOINT ABNORMALITIES
NOBIVAC® LYME IS SHOWN TO BE EFFECTIVE AGAINST SUBCLINICAL ARTHRITIS, IN ADDITION TO CLINICAL DISEASE5
Following vaccination with Nobivac Lyme:
No Borrelia burgdorferi were found in the joint
No joint inflammation, stiffness, or lameness were observed5
40% of control dogs developed chronic joint inflammation5
27% of control dogs developed joint stiffness or lameness5
Dogs exhibited no signs of Lyme disease–associated joint abnormalities5
TICK CHALLENGE STUDY
NOBIVAC® LYME IS HIGHLY EFFECTIVE IN KILLING BORRELIA BURGDORFERI AND PREVENTING INFECTION5
Tick challenge study confirms effectiveness.5
Following vaccination with Nobivac Lyme, no B. burgdorferi were found.
The tick challenge study was a placebo-controlled trial involving thirty 8-week-old puppies. Dogs were challenged 3 weeks following second vaccination.
No items to show.
Loading…
NOBIVAC LYME IS A SAFE CHOICE
Proven safe and well tolerated in a field safety trial of more than 600 dogs
99.3% reaction-free
Since 2009, Nobivac® Lyme has been safely administered to over 4 million dogs